Novo Nordisk, a leading Danish pharmaceutical company, has partnered with Anthropic, an AI research organization, to enhance its drug discovery and development processes. This collaboration focuses on integrating Anthropic's advanced AI models, including Claude Science, into Novo's research workflows to address specific scientific challenges and accelerate the creation of new medicines. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/09/16/3363106/0/en/novo-and-anthropic-will-collaborate-to-advance-drug-discovery-with-claude.html?utm source=openai))
The partnership aims to leverage AI to improve biological reasoning and software engineering within Novo's research and development (R&D) organization. By utilizing Anthropic's frontier models, Novo intends to streamline R&D processes, reduce the time from research to market, and uncover new scientific opportunities in understanding human biology and drug mechanisms. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/09/16/3363106/0/en/novo-and-anthropic-will-collaborate-to-advance-drug-discovery-with-claude.html?utm source=openai))
Mike Doustdar, president and CEO of Novo, emphasized the significance of this collaboration, stating, "Joining forces with Anthropic will supercharge our R&D organization and help us on our mission to bring new, transformative health solutions to people living with chronic diseases." ([globenewswire.com](https://www.globenewswire.com/news-release/2026/09/16/3363106/0/en/novo-and-anthropic-will-collaborate-to-advance-drug-discovery-with-claude.html?utm source=openai))
Dario Amodei, co-founder and CEO of Anthropic, highlighted the potential impact of AI in accelerating medical breakthroughs, noting, "AI’s increasing capability brings with it the potential to compress a century’s worth of biological and medical breakthroughs into a decade." ([globenewswire.com](https://www.globenewswire.com/news-release/2026/09/16/3363106/0/en/novo-and-anthropic-will-collaborate-to-advance-drug-discovery-with-claude.html?utm source=openai))
This collaboration is part of Novo's broader strategy to become a leader in AI-driven healthcare, building on existing AI initiatives with other technology partners. The partnership is designed with robust data governance and human oversight to ensure responsible and ethical application of AI in biomedical contexts. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/09/16/3363106/0/en/novo-and-anthropic-will-collaborate-to-advance-drug-discovery-with-claude.html?utm source=openai))
The initial phase of the collaboration will involve testing Claude Science in specific R&D workflows, focusing on areas where the combined capabilities of Novo and Anthropic are expected to have the greatest impact. This approach aims to address key drug discovery challenges identified by Novo's scientists and computational teams. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/09/16/3363106/0/en/novo-and-anthropic-will-collaborate-to-advance-drug-discovery-with-claude.html?utm source=openai))
By integrating Anthropic's AI models, Novo seeks to enhance its R&D productivity and accelerate the development of new medicines, ultimately improving health outcomes for individuals with chronic diseases. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/09/16/3363106/0/en/novo-and-anthropic-will-collaborate-to-advance-drug-discovery-with-claude.html?utm source=openai))